Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1626 - Eight-year follow up results of the OTOASOR Trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. A randomized, single centre, phase III, non-inferiority trial


11 Sep 2017


Poster display session


Ákos Sávolt


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


Á. Sávolt1, G. Peley1, C. Polgár2, B. Győrffy3, Z. Mátrai1

Author affiliations

  • 1 Department Of Breast And Sarcoma Surgery, National Institute of Oncology Hungary, 1122 - Budapest/HU
  • 2 Center Of Radiotherapy, National Institute of Oncology Hungary, 1122 - Budapest/HU
  • 3 Mta Ttk Momentum Cancer Biomarker Res. Group, Hungarian Academy of Sciences, Budapest, Hungary, 1122 - Budapest/HU


Abstract 1626


The National Institute of Oncology, Budapest conducted a single centre randomized clinical study. The OTOASOR (Optimal Treatment Of the Axilla – Surgery Or Radiotherapy) trial compares completion of axillary lymph node dissection (cALND) to regional nodal irradiation (RNI) in patients with sentinel lymph node metastasis (pN1sn) in stage I-II breast cancer.


Patients with primary invasive breast cancer (cN0 and cT ≤ 3cm) were randomized before surgery for cALND (standard treatment) or RNI (investigational treatment). Sentinel lymph nodes (SN) were investigated with serial sectioning at 0.5 mm levels by haematoxylin-eosin staining. Investigational treatment arm patients received 50Gy RNI instead of cALND. Adjuvant treatment and follow up were performed according to the actual guidelines. Between August 2002 and June 2009, 1,054 patients were randomized for cALND and 1052 patients for RNI. SN was evaluated in 2,073 patients and was positive in 526 patients (25.4%). 474 cases were evaluable (244 in the cALND and 230 in the RNI arm), and in the cALND group 94 of 244 patients (38.5%) who underwent completion axillary surgery has additional positive nodes. The two arms were well balanced according to the majority of main prognostic factors. Primary endpoint was axillary recurrence and secondary endpoints were overall survival (OS) and disease-free survival (DFS).


Mean follow-up was 97 months (Q1-Q3 80-120). Axillary recurrence was 2.0% in cALND arm vs. 1.7% in RNI arm (P = 1.00). OS at 8 years was 77.9% vs. 84.8% (P = 0.060), and DFS was 72.1% in cALND arm and 77.4% after RNI (P = 0.51). The results show that RNI is statistically not inferior to cALND treatment.


The long term follow-up results of this prospective-randomized trial suggest that RNI without cALND does not increase the risk of axillary failure in selected patients with early-stage invasive breast cancer (cT ≤ 3 cm, cN0) and pN1(sn). Axillary radiotherapy should be an alternative treatment for selected patients with sentinel lymph node metastases.

Clinical trial identification

Legal entity responsible for the study

The trial was approved by the National Institute of Oncology’s Ethical Committee




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.